3-Trimethylenedithiomethyl-2-cyclohexen-2-one | 125991-67-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-Trimethylenedithiomethyl-2-cyclohexen-2-one
• 英文别名: 3-(1,3-dithian-2-yl)cyclohex-2-en-1-one；3-[1,3]dithian-2-yl-cyclohex-2-enone
• CAS: 125991-67-5
• 化学式: C₁₀H₁₄OS₂
• 分子量: 214.353
• InChiKey: WODYOSOBJNQVFH-UHFFFAOYSA-N

物化性质

• 沸点：
  376.9±42.0 °C(Predicted)
• 密度：
  1.236±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  67.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-Trimethylenedithiomethyl-2-cyclohexen-2-one 在 N-氯代丁二酰亚胺 、 对甲苯磺酸 、 silver nitrate 、 zinc(II) chloride 、 lithium diisopropyl amide 作用下， 以 水 、 乙腈 为溶剂， 反应 3.5h， 生成 3-(二甲氧基甲基)-6-(2-羟基-2-丙基)-2-环己烯-1-酮
  参考文献：
  名称：

  Kuwahara, Shigefumi; Suzuki, Katsuyuki; Hiramatsu, Akira, Bioscience, Biotechnology and Biochemistry, 1992, vol. 56, # 9, p. 1510 - 1511

  摘要：

  DOI：
• 作为产物：
  描述：

  在 硫酸 作用下， 以 四氢呋喃 、 正己烷 、 水 为溶剂， 反应 2.0h， 生成 3-Trimethylenedithiomethyl-2-cyclohexen-2-one
  参考文献：
  名称：

  Kuwahara, Shigefumi; Suzuki, Katsuyuki; Hiramatsu, Akira, Bioscience, Biotechnology and Biochemistry, 1992, vol. 56, # 9, p. 1510 - 1511

  摘要：

  DOI：

文献信息

• A Tandem Horner−Emmons Olefination−Conjugate Addition Approach to the Synthesis of 1,5-Disubstituted-6-azabicyclo[3.2.1]octanes Based on the AE Ring Structure of the Norditerpenoid Alkaloid Methyllycaconitine
  作者：David J. Callis、Noel F. Thomas、David P. J. Pearson、Barry V. L. Potter

  DOI：10.1021/jo9519672

  日期：1996.1.1

  A novel Horner-Emmons olefination conjugate addition reaction of N-acetylamides to form 1,5-disubstituted-6-azabicyclo[3.2.1]octanes with two bridgehead quarternary carbon centers is reported. This reaction is a key step in an approach to the synthesis of small ring analogues based on the AE ring structure of the Delphinium norditerpenoid, methyllycaconitine (MLA) (1). Initially, 3-(hydroxymethyl)cyclohex-2-en-1-one

  报道了一种新颖的N-乙酰酰胺的霍纳-埃蒙斯烯化共轭加成反应，形成带有两个桥头四元碳中心的1，5-二取代-6-氮杂双环[3.2.1]辛烷。该反应是基于Delphinium norditerpenoidoid，甲基lycaconitine（MLA）的AE环结构合成小环类似物的关键步骤。最初，选择3-（羟甲基）环己基-2-烯-1-酮（10）作为这些结构的起始材料，但事实证明生成效率低下。相反，3-[（（苯硫基）甲基]环己-2-烯-1-酮（6）和3-（1,3-二噻-2--2-基）环己-2-烯-1-酮（ 11）收成良好。随后进行氢氰化，缩酮化，还原，乙酰化，缩醛脱保护，和霍纳-埃蒙斯烯烃共轭加成反应形成1-[（（苯硫基）甲基] -5-[（乙氧羰基）甲基] -6-乙酰氨基-6-氮杂双环[3.2.1]辛烷（28），1-（1分别报道了，3-二噻二-2-基）-5-[（乙氧羰基）甲基] -6-乙酰基-6-氮杂双环[3
• SUBSTITUTED FLUOROETHYL UREAS AS ALPHA 2 ADRENERGIC AGENTS
  申请人：Chow Ken

  公开号：US20080255239A1

  公开（公告）日：2008-10-16

  Therapeutic compounds, and methods, compositions, and medicaments related thereto are disclosed herein.

  本文揭示了治疗化合物、方法、组合物和相关药物。
• Heterocyclic aspartyl protease inhibitors
  申请人：Zhu Zhaoning

  公开号：US20080200445A1

  公开（公告）日：2008-08-21

  Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W is a bond, —C(═S)—, —S(O)—, —S(O) 2 —, —C(═O)—, —O—, —C(R 6 )(R 7 )—, —N(R 5 )— or —C(═N(R 5 ))—; X is —O—, —N(R 5 )— or —C(R 6 )(R 7 )—; provided that when X is —O—, U is not —O—, —S(O)—, —S(O) 2 —, —C(═O)— or —C(═NR 5 )—; U is a bond, —S(O)—, —S(O) 2 —, —C(O)—, —O—, —P(O)(OR 15 )—, —C(═NR 5 )—, —(C(R 6 )(R 7 )) b — or —N(R 5 )—; wherein b is 1 or 2; provided that when W is —S(O)—, —S(O) 2 —, —O—, or —N(R 5 )—, U is not —S(O)—, —S(O) 2 —, —O—, or —N(R 5 )—; provided that when X is —N(R 5 )— and W is —S(O)—, —S(O) 2 —, —O—, or —N(R 5 )—, then U is not a bond; and R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , and R 7 are as defined in the specification; and pharmaceutical compositions comprising the compounds of formula 1. Also disclosed is the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases, and the methods of inhibiting of Human Immunodeficiency Virus, plasmepins, cathepsin D and protozoal enzymes. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic m 1 agonist or m 2 antagonist.

  本发明涉及公式I的化合物或其立体异构体、互变异构体或药学上可接受的盐或溶剂，其中W是键，—C(═S)—，—S(O)—，—S(O)2—，—C(═O)—，—O—，—C(R6)(R7)—，—N(R5)—或—C(═N(R5))—；X是—O—，—N(R5)—或—C(R6)(R7)—；但当X为—O—时，U不是—O—，—S(O)—，—S(O)2—，—C(═O)—或—C(═NR5)—；U是键，—S(O)—，—S(O)2—，—C(O)—，—O—，—P(O)(OR15)—，—C(═NR5)—，—(C(R6)(R7))b—或—N(R5)—；其中b为1或2；但当W为—S(O)—，—S(O)2—，—O—或—N(R5)—时，U不是—S(O)—，—S(O)2—，—O—或—N(R5)—；当X为—N(R5)—且W为—S(O)—，—S(O)2—，—O—或—N(R5)—时，U不是键；R1、R2、R3、R4、R5、R6和R7如规范中所定义；以及包括公式1的化合物的药物组合物。本发明还涉及抑制天冬氨酸蛋白酶的方法，特别是治疗心血管疾病、认知和神经退行性疾病的方法，以及抑制人类免疫缺陷病毒、贫血原虫、D蛋白酶和原虫酶的方法。本发明还涉及使用公式I的化合物与胆碱酯酶抑制剂或肌动蛋白m1受体激动剂或m2受体拮抗剂相结合治疗认知或神经退行性疾病的方法。
• HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS
  申请人：Zhu Zhaoning

  公开号：US20090258868A1

  公开（公告）日：2009-10-15

  Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W is a bond, —C(═S)—, —S(O)—, —S(O) 2 —, —C(═O)—, —O—, —C(R 6 )(R 7 )—, —N(R 5 )— or —C(═N(R 5 ))—; X is —O—, —N(R 5 )— or —C(R 6 )(R 7 )—; provided that when X is —O—, U is not —O—, —S(O)—, —S(O) 2 —, —C(═O)— or —C(═NR 5 )—; U is a bond, —S(O)—, —S(O) 2 —, —C(O)—, —O—, —P(O)(OR 15 )—, —C(═NR 5 )—, —(C(R 6 )(R 7 )) b — or —N(R 5 )—; wherein b is 1 or 2; provided that when W is —S(O)—, —S(O) 2 —, —O—, or —N(R 5 )—, U is not —S(O)—, —S(O) 2 —, —O—, or —N(R 5 )—; provided that when X is —N(R 5 )— and W is —S(O)—, —S(O) 2 —, —O—, or —N(R 5 )—, then U is not a bond; and R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , and R 7 are as defined in the specification; and pharmaceutical compositions comprising the compounds of formula I. Also disclosed is the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases, and the methods of inhibiting of Human Immunodeficiency Virus, plasmepins, cathepsin D and protozoal enzymes. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic m 1 agonist or m 2 antagonist.

  本发明涉及公式I的化合物或其立体异构体，互变异构体，或其药学上可接受的盐或溶剂，其中W是键，—C(═S)—，—S(O)—，—S(O)2—，—C(═O)—，—O—，—C(R6)(R7)—，—N(R5)—或—C(═N(R5))—；X是—O—，—N(R5)—或—C(R6)(R7)—；前提是当X为—O—时，U不是—O—，—S(O)—，—S(O)2—，—C(═O)—或—C(═NR5)—；U是键，—S(O)—，—S(O)2—，—C(O)—，—O—，—P(O)(OR15)—，—C(═NR5)—，—(C(R6)(R7))b—或—N(R5)—；其中b为1或2；前提是当W为—S(O)—，—S(O)2—，—O—或—N(R5)—时，U不是—S(O)—，—S(O)2—，—O—或—N(R5)—；前提是当X为—N(R5)—，W为—S(O)—，—S(O)2—，—O—或—N(R5)—时，U不是键；以及R1，R2，R3，R4，R5，R6和R7如规范中所定义的；以及包括公式I的化合物的药物组合物。本发明还涉及抑制天冬氨酸蛋白酶的方法，特别是治疗心血管疾病、认知和神经退行性疾病的方法，以及抑制人类免疫缺陷病毒、质膜蛋白酶、D蛋白酶和原虫酶的方法。本发明还涉及使用公式I的化合物与胆碱酯酶抑制剂或肌动蛋白m1激动剂或m2拮抗剂相结合治疗认知或神经退行性疾病的方法。
• LIPSHUTZ, BRUCE H.;UNG, CHRISTOPHER;SENGUPTA, SAUMITRA, SYNLETT.,(1989) N, C. 64-66
  作者：LIPSHUTZ, BRUCE H.、UNG, CHRISTOPHER、SENGUPTA, SAUMITRA

  DOI：——

  日期：——